Brief: HBM Holdings Says China's NMPA Has Approved Group's IND Application For HBM4003
10/09/2021 11:32
Sept 10 (Reuters) - Hbm Holdings Ltd 2142.HK :
* NMPA OF CHINA HAS APPROVED GROUP'S INVESTIGATIONAL NEW
DRUG
APPLICATION FOR HBM4003
Further company coverage: 2142.HK
(Reporting by Harshita Swaminathan)
((Harshita.Swaminathan@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study